sales@dcchemicals.com
BP-200-C12
Formulation & Performance
Formulation & Performance
Study-specific compositions, preparation conditions and experimental outcomes for BP-200-C12.
Main paper and SI reviewed; free LNP, mineral-bound mRNA delivery and siRNA experiments are separated.
1. Formulations and component amounts
Reported composition and calculated mass are separate. Molecular-weight inputs use the current catalog values; DMG-PEG2000 is fixed initially at 2507. Edit inputs only when using a verified alternative material.
MiTEX
mol%Main Methods
| Component | Molecular weight | Reported molar entry | Calculated mass |
|---|---|---|---|
| BP-200-C12 | 2374.6 | 35 | Not calculated |
| DOPE | 744.03 | 16 | Not calculated |
| Cholesterol | 386.65 | 46.5 | Not calculated |
| 14:0 PEG2000 PE | Not confirmed | 2.5 | Not calculated |
No complete mass recipe is generated for this formulation while composition or identity-dependent inputs remain unresolved.
How component weights are calculated
For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.
2. Preparation and experimental setup
| Parameter | Reported procedure / limitation | Source |
|---|---|---|
| LNP formation | Ethanolic lipid phase mixed with citrate-buffered aqueous RNA by vigorous pipetting; dialysis against 1× PBS for 2 h; 0.22 µm filtration. | Methods; exact buffer pH, phase ratio and mixing rate not recovered |
| N/P / mass ratio | N/P and a directly verified lipid:RNA mass ratio are not established here. | No conversion from particle size or loading is attempted |
| Reported lipid batch | BP-200-C12 2.20 × 10⁻⁷ mol; DOPE 1.01 × 10⁻⁷; cholesterol 2.92 × 10⁻⁷; PEG lipid 1.57 × 10⁻⁸. | Main Methods; rounded values |
| HA-disc workflow | 10 × 2 mm HA discs; overnight preconditioning in DMEM + 0.2% collagen; incubate with 150 µL LNP containing 2,000 ng RNA at 37 °C with shaking for 24 h; wash; seed 50,000 BJ cells or 100,000 mMSCs. | Methods; assay readout 48 h after seeding |
| Bone-graft experiment | 4 million tdROSA mMSCs, 40 mg HA/TCP and 20 µL LNP at 520 ng RNA/µL per implant; subcutaneous implantation in nude mice. | Methods; RNA per implant = 10.4 µg, calculated |
3. Particle characterization
| Measurement / batch | Reported result | Evidence context |
|---|---|---|
| siMiTEX (siRNA formulation) | 154.3 nm; PDI 0.203; zeta potential −29.28 mV | SI Fig. S13; not transferred to the mRNA-loaded batch |
| PEG-lipid identity | 14:0 PEG2000 PE is a phospholipid-linked PEG component | Methods; not DMG-PEG2000 |
| Complete mass conversion | Withheld until the exact PEG material molecular-weight basis is confirmed | DOPE and cholesterol values alone do not define the full mass recipe |
4. Performance by experiment
| Experiment and dose | Readout and comparator | Result and source |
|---|---|---|
| Free LNP at low RNA dose mMSCs; Cre mRNA; 20 ng / 20,000 cells | Readout: SI assay endpoint Comparator: C12-200 LNP | MiTEX 22.9% versus C12-200 57.5% reporter-positive cells: MiTEX is inferior in this free-particle condition.SI Fig. S4 |
| Free LNP at higher dose mMSCs; Cre mRNA; 200 ng / 20,000 cells | Readout: SI assay endpoint Comparator: C12-200 LNP | 71.2% versus 70.3%; no significant difference reported.SI Fig. S4 |
| Mineral binding HA binding assay; fluorescent-lipid tracking | Readout: 120 min Comparator: C12-200 LNP | Approximately 80% versus 10% bound at 120 min. This kinetic assay is distinct from the 24 h disc-loading workflow.Fig. 2 / mineral-binding study |
| After-wash HA retention HA discs; 2,000 ng mRNA input | Readout: After loading and washing Comparator: C12-200 LNP | Approximately 200 ng retained with MiTEX versus <50 ng with control LNPs. Input dose and retained dose are different quantities.Fig. 3b |
| Mineral-mediated Cre delivery mMSCs seeded on loaded HA discs; Cre reporter | Readout: 48 h after seeding Comparator: C12-200 LNP on HA | Approximately 80% versus 17.92% reporter-positive cells. The advantage appears in the mineral-bound delivery context.Fig. 3e–f |
| STAT3 silencing Gingival fibroblasts; STAT3 siRNA, 1–100 nM | Readout: 24 h Comparator: Control formulation and untreated cells | >90% knockdown at 50 and 100 nM; both tested carrier systems exceed 90% at 50 nM. No superiority is inferred from this endpoint alone.siRNA results; SI characterization |
| Bone-graft reporter persistence Subcutaneous HA/TCP/mMSC implant with Cre-mRNA LNP | Readout: Results describe 60 days; Methods describe 8 weeks Comparator: Control-graft conditions | Reporter evidence is evaluated in an implanted scaffold/cell system, not as direct systemic bone targeting. The duration wording is retained as a source discrepancy.Bone-graft Results and Methods |
Mechanistic evidence
The experiments support hydroxyapatite association and delivery from a mineral surface. They do not establish that all bisphosphonate LNPs outperform C12-200 in suspension.
5. Interpretation and unresolved details
- Bisphosphonate-mediated mineral association is central to the reported benefit. Low-dose free LNP delivery is not universally improved.
- Do not substitute DMG-PEG2000 for the reported 14:0 PEG2000 PE without making a new formulation.
- The scaffold study describes 60 days in Results and 8 weeks in Methods; no exact equivalence is assumed.
Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.
6. References and data access
Liu J, et al. Chemically Tailored Lipids Mediate Solid-phase RNA Programming of Mineralized Microenvironments. Biomaterials (2026), article 124680. doi:10.1016/j.biomaterials.2026.124680
DOI: 10.1016/j.biomaterials.2026.124680
Download experiment table (CSV) · Open printable Formulation & Performance guide
Revision FP-20261022 · Source review: 22 October 2026 · DC Chemicals